A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Obstructive Pulmonary Disease (COPD). Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Patients must have moderate or severe COPD

• Patients must have at least one episode of COPD-related symptoms (eg, cough, sputum production, shortness of breath) within 2 months prior to screening Exclusion Criteria:

• Patients must not have asthma as main component of obstructive airway disease

• Patients must not have had a moderate or severe exacerbation of COPD within previous 1 month